Both competitors have promising lead programs, and enough cash, too.Altimmune (ALT 0.14%) and Viking Therapeutics (VKTX 6.16%) are a pair of biotechs planning to follow in the footsteps of Novo Nordisk and Eli Lilly and develop GLP-1-targeted medicines for obesity like Wegovy and Zepbound. Both companies have a plausible pathway to continue making their investors wealthier, perhaps by quite a bit.But which one is a better stock to buy right now? Join me in analyzing each, and we'll figure it out together.Th ...